DICLOFENAC

Arthritis

Express Specialty PharmacySmall moleculeDormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 89/ 100

Competitive context

2 Active assets in the Arthritis cohort.

Asset / Sponsor	Phase	Rating
DICLOFENAC Express Specialty Pharmacy	Phase 4	BBB
PROPOFOL Pedro Paulo Tanaka	Phase 4	BB
Desflurane Pedro Paulo Tanaka	Phase 4	BB
TESTOSTERONE UNDECYLATE Alliance for Clinical Trials in Oncology	Phase 3	BB
Letrozole ARKAY Therapeutics	Phase 2	BB

View all 33 →

Same molecule, other indications

DICLOFENAC is also rated in:

arthropathyDormant

BBB

Indicative ·

73 / 100

Surgical Wound InfiltrationDormant

BB

Indicative ·

69 / 100

Lymph Node DissectionDormant

BB

Indicative ·

69 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.